News & Updates

TORONTO, CANADA / ACCESSWIRE / October 15, 2024 - Ripple Therapeutics Corporation, a clinical stage company focused on improving ophthalmic therapeutics with controllable sustained delivery implants, is pleased to announce evaluation and licensing agreements with Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal disease. Ripple’s patented technology platform is based on a discovery that drugs can be chemically engineered into controlled release pharmaceuticals without the use of polymers or excipients. These proprietary prodrugs undergo surface erosion to give zero order release kinetics and are highly engineerable to tailor both drug dose and duration. The advantages of this technology include lower molecular weight and higher drug loading allowing for smaller implants and a lack of degradation products which provides both a clearer regulatory path as well as an improved safety profile. With an extended duration of therapeutic benefit, this technology will also reduce the treatment burden for patients. These agreements enable Glaukos to leverage Ripple’s proprietary technology platform to create sustained release implants of targeted APIs for both glaucoma and retinal diseases. If the program is successful, the evaluation agreement will automatically convert into a licensing agreement with future milestone payments and royalties. “We believe Ripple has one of the most promising drug delivery technologies currently under development,” commented Tomas Navratil, PhD, Chief Development Officer, Glaukos. “We are pleased with the progress of our collaboration and have enjoyed working with the Ripple team as we work together to bring these much-needed sustained release products to patients with critical unmet needs.” “This is the first of what we believe will be a number of transactions using our technology platform in concert with partners’ APIs to create sustained release implants which will benefit patients with extended duration and improved safety”, commented Tom Reeves, President & CEO, Ripple Therapeutics. “We look forward to continued collaboration with the entire Glaukos team.” About Ripple Therapeutics Ripple Therapeutics Corporation is a privately held clinical stage company focused on improving ophthalmic therapeutics with controllable sustained delivery implants. Ripple’s patented technology platform is based on a discovery that drugs can be chemically engineered into controlled release pharmaceuticals without the use of polymers or excipients. These proprietary prodrugs undergo surface erosion to give zero order release kinetics and are highly engineerable to tailor both drug dose and duration. The advantages of this technology include lower molecular weight and higher drug loading allowing for smaller implants and a lack of degradation products which provides both a clearer regulatory path as well as an improved safety profile. With an extended duration of therapeutic benefit, this technology will also reduce the treatment burden for patients. www.rippletherapeutics.com Media Contact (Ripple) Julie Fotheringham, V.P. Marketing, People & Culture, Ripple Therapeutics M: 416-951-7988 E: jfotheringham@rippletherapeutics.com

Hemal Mehta, MBBS, MD (Cantab.), presented Efficacy and safety of the low dose dexamethasone IBE-814 IVT Implant for diabetic macular edema and retinal vein occlusion: Results of a first-in-human Phase 2 trial, at Euretina Congress in Barcelona, Spain, September 19-22, 2024. View Presentation

- Collaboration to leverage AbbVie's eye care expertise and Ripple’s innovative drug delivery platform to develop next-generation sustained release drug delivery implants for the treatment of glaucoma TORONTO, CANADA / ACCESSWIRE / September 17, 2024 / − Ripple Therapeutics today announced a collaboration and option-to-license agreement with AbbVie to develop RTC-620, a next generation, fully biodegradable, sustained release drug delivery intracameral implant with repeat dosing capabilities to reduce intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). This collaboration leverages AbbVie's expertise in eye care and Ripple’s innovative drug delivery platform. Ripple’s patented technology platform is based on a discovery that drugs can be engineered into controlled release pharmaceuticals without the use of polymers or excipients. These proprietary prodrugs undergo surface erosion to give zero order release kinetics and are highly customizable to tailor both drug dose and duration. Because there are no polymers or excipients, once the drug is gone, the implant is gone with no pro-inflammatory degradation products, which supports repeat dosing. “We’re pleased to partner with AbbVie, a worldwide leader in ophthalmic therapeutics,” said Tom Reeves,President and Chief Executive Officer, Ripple Therapeutics. “By combining our drug delivery platform with AbbVie’s research, clinical, regulatory and commercial capabilities, we hope to deliver a meaningful impact on the lives of people living with glaucoma.” Millions of people are living with glaucoma, one of the leading causes of vision loss. New treatment options areneeded to help patients challenged with topical drops or who are at risk for vision loss and looking for alternative treatment options. "At AbbVie, we strive to find innovative solutions to build our portfolio of vision-preserving therapies,” said Michael Robinson, M.D., Vice President and Therapeutic Area Head, Ophthalmology, AbbVie. “We are excited to partner with Ripple to further advance the development of RTC-620." Under terms of the agreement, Ripple will lead preclinical development of RTC-620. Upon exercise of the option, AbbVie will lead the clinical and commercialization activities. Ripple will receive an upfront payment of $21.8 million from AbbVie and is eligible to receive up to $290 million in aggregate option fees and milestones, as well as tiered royalties on net sales. About Ripple Therapeutics Ripple Therapeutics Corporation is a privately held clinical stage company focused on improving ophthalmic therapeutics with controllable sustained delivery implants without the use of polymers or excipients. Our novel therapeutics provide better outcomes for patients, easier management of care for physicians and lower cost for payors. www.rippletherapeutics.com Piper Sandler acted as the exclusive financial advisor to Ripple. For further information: Media: Julie Fotheringham, jfotheringham@rippletherapeutics.com

On May 12, 2024, Baruch Kupperman, MD, PhD, presented Ripple Therapeutics Steroid Drug Delivery Clinical Trial for DME and RVO in the Late Breakers Session, 11:15am. View Presentation

Ocular tolerability and IOP-lowering evaluation of the RTC-620 intracameral implant in normotensive beagle dogs Ike Iqbal K Ahmed, Kyle Battiston, Shadi Taghavi, Mahta Massoud, Eamon Kelly, Hans Fischer, Dimitra Louka, Matthew Statham, Jonathan Day, Adam Daley, Ian Parrag, Wendy Naimark View Presentation Video View Presentation

TORONTO, ON, CANADA / APRIL 4, 2024 - Ripple Therapeutics Corporation, a clinical stage company focused on improving ophthalmic therapeutics with controllable sustained delivery implants, was pleased to present at Eyecelerator @ ASCRS 2024 in Boston.

TORONTO, ON, CANADA / MARCH 28, 2024 - Ripple Therapeutics Corporation, a clinical stage, ophthalmology-focused developer of novel therapeutics, is presenting findings from the RIPPLE-1 clinical trial of the IBE-814 IVT Implant at a number of key Ophthalmology conferences. Results from RIPPLE-1 showed reduced CST and improved or stable BCVA at Month 6 in all cohorts (high dose and low dose, DME and RVO), a reduction in treatment burden compared to pre-study and safety comparable to other intravitreal steroids. Long-term follow-up is now complete, and analysis of the final data set is in progress. The IBE-814 IVT Implant is comprised solely of a prodrug, IBE-814, and enables sustained dexamethasone delivery to the retina over a period of at least 6 months. The implant is administered by intravitreal injection using a 30G needle. RIPPLE-1 was a first-in-human phase II, multi-center, single-masked dose-ranging study designed to evaluate the safety, efficacy, and durability of two dosage regimens of the IBE-814 IVT Implant. The study enrolled 60participants with diabetic macular edema (DME) and retinal vein occlusion (RVO). Participants were randomized to receive either the low dose (70 µg) dexamethasone, one implant) or high dose implant (140 µg dexamethasone, two implants) and were followed for up to 18 months post-baseline treatment. Presented: American Academy of Ophthalmology (AAO) Date: November 4, 2023 Presenter: Sumit Sharma, MD, FASRS Title: Intravitreal Sustained-Release Dexamethasone Implant for DME and RVO: 6-Month Results from the First In-Human Phase 2 RIPPLE-1 Trial View Presentation Hawaiian Eye and Retina Date: January 18, 2024 Presenter: Sumit Sharma, MD, FASRS Title: Intravitreal Sustained-Release Dexamethasone Implant for DME and RVO: 9-Month Results from the First In-Human Phase 2 RIPPLE-1 Trial View Presentation Angiogenesis, Exudation, and Degeneration Date: February 3, 2024 Presenter: Baruch Kuppermann, MD, PhD Title: Intravitreal Sustained-Release Dexamethasone Implant for DME and RVO: Interim Results from the First In-Human Phase 2 RIPPLE-1 Trial View Presentation Accepted: The Association for Research in Vision and Ophthalmology (ARVO ) Date: May 9, 2024 Session: 530 Diabetic macular edema, 11:45 am Presenter: Hemal Mehta, MBBS MD(Cantab.) FRCOphth FRANZCO Title: Efficacy and safety of a low dose dexamethasone implant for diabetic macular edema and retinal vein occlusion: Results of the first-in-human phase 2 RIPPLE-1 trial Date: May 7, 2024 Session: 320 Retinitis pigmentosa and macular diseases, 8:30 am Presenter: Wendy Naimark, PhD, on behalf of Kelli Wootton, MASc Title: IBE-814 IVT Implants demonstrate a treatment burden reduction in subjects with DME and RVO due to extended-release of dexamethasone: An analysis of the first-in-human phase 2 RIPPLE-1 trial Retina World Congress Date: May 12, 2024, Session: Late Breakers, 11:15 am Presenter: Baruch Kuppermann, MD, PhD Title: Ripple Therapeutics Steroid Drug Delivery Clinical Trial for DME and RVO About Ripple Therapeutics Ripple Therapeutics Corporation is a clinical stage, privately held company that is focused on ophthalmic therapeutics with controllable, sustainable drug delivery. The core feature of Ripple’s Epidel™ technology is the ability to engineer sustained-release pharmaceuticals with surface erosion release kinetics without the use of polymers or excipients. Ripple’s novel therapeutics provide for better outcomes for patients, easier management of care for physicians and lower costs for payors. Ripple has a full product pipeline in development. www.rippletherapeutics.com  Media Contact Julie Fotheringham, V.P. Marketing, People & Culture M: 416-951-7988 E: jfotheringham@rippletherapeutics.com

Lisbon, March 20, 2023, Hovione, the specialist integrated CDMO, leader in spray drying and particle engineering, and Ripple Therapeutics, a leading ophthalmic sustained drug delivery company, have entered a strategic partnership to expand the use of Ripple's Epidel® platform beyond ophthalmic applications. The core feature of Ripple’s Epidel® technology is the ability to deliver sustained-release pharmaceuticals with surface erosion release kinetics without the use of polymers or excipients. This enables higher drug loading, smaller size implants, defined and predictable biocompatible degradation products with straightforward and scalable manufacturing processes. Surface erosion-based drug release provides a highly effective way to control dose and duration. By incorporating Ripple's Epidel® platform into its toolbox, Hovione can expand its portfolio of novel drug delivery solutions to the pharmaceutical industry. “The combination of technology synergy, innovative vision and cultural fit makes collaborating with Hovione an exciting next step in the advancement of the Epidel® platform beyond the ophthalmic field,” stated Dr. Wendy Naimark, Ripple co-founder and Chief Technology Officer. “Hovione’s expertise in controlled, sustained drug delivery, along with their experience in chemical synthesis and pharmaceutical manufacturing, makes for a great partnership.” "We are thrilled to partner with Ripple, who developed a state-of-the-art platform for sustained release," says Dr. Jean-Luc Herbeaux, Hovione's CEO. " Our shared goal is to accelerate and broaden the access to this highly innovative and enabling technology for the benefit of our pharmaceutical customers and their patients worldwide." By extending the use of the Epidel® platform beyond ocular applications, this partnership will enable the development of a diverse range of new products with optimal sustained release profiles. About Hovione: Hovione is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations. As a Contract Development and Manufacturing Organization (CDMO) with a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four FDA inspected sites in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. Hovione provides pharmaceutical customers services for the development and compliant manufacture of innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, Hovione offers a complete range of services, from API, formulation development and devices. Hovione's culture is based on innovation, quality and dependability. Hovione was the first Chemical/ Pharmaceutical Company to become a Certified B Corp, is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards. About Ripple Therapeutics: Ripple Therapeutics Corporation is a clinical stage, privately held company that is focused on ophthalmic therapeutics with controllable, sustainable drug delivery. The core feature of Ripple’s Epidel™ technology is the ability to engineer sustained-release pharmaceuticals with surface erosion release kinetics without the use of polymers or excipients. Ripple’s novel therapeutics provide for better outcomes for patients, easier management of care for physicians and lower costs for payors. Ripple has a full product pipeline in development. www.rippletherapeutics.com For more information, please visit www .hovione.com or contact: Vanessa Romeu | Communications Director | vromeu@hovione.com |Tel: +351 21 982 9000 Or visit www.rippletherapeutics.com or contact: Julie Fotheringham | V.P. Marketing, People & Culture | 416-951-7988| jfotheringham@rippletherapeutics.com

TORONTO, ON, CANADA / JANUARY 24, 2023 - Ripple Therapeutics is proud to announce that our organization has been named on the 2023 Best Workplaces for Start-ups. Ripple received this honour after a thorough and independent analysis conducted by Great Place to Work®. The list is based on direct feedback from employees of the hundreds of organizations that were surveyed by Great Place to Work®. To be eligible for this list, organizations must be Great Place to Work- Certified™ and have exceptionally high scores from employees on the Trust Index survey. “At Ripple, we are intentional about investing in people”, commented Tom Reeves, President & CEO. “Our core values emphasize that we care, we collaborate, and we have fun while persevering to find innovative solutions to complex problems. As such, it’s great to receive this independent third-party validation that we are a great place to work.” About Ripple Therapeutics Ripple Therapeutics Corporation is a clinical stage, privately held company that is focused on ophthalmic therapeutics with controllable, sustainable drug delivery. The core feature of Ripple’s Epidel™ technology is the ability to engineer sustained-release pharmaceuticals with zero-order release kinetics without the use of polymers or excipients. Ripple has a full product pipeline in development. www.rippletherapeutics.com About Great Place to Work® Great Place to Work is the global authority on high-trust, high-performance workplace cultures. Through proprietary assessment tools, advisory services, and certification programs, Great Place to Work recognizes Canada’s Best Workplaces in a series of national lists including those published by The Globe & Mail (Canada) and Fortune magazine (USA). Great Place to Work provides the benchmarks, framework, and expertise needed to create, sustain, and recognize outstanding workplace cultures. Visit us at www.greatplacetowork.ca or find us on Twitter at @GPTW_Canada. Media Contact Julie Fotheringham, V.P. Marketing, People & Culture M: 416-951-7988 E: jfotheringham@rippletherapeutics.com